Tracker › Companies › Fulcrum Therapeutics, Inc.
2 No sign of it. We found no public evidence tying Fulcrum Therapeutics, Inc.'s cuts to AI.
Every tracked 2026 layoff at Fulcrum Therapeutics, Inc., newest first. Scores are 0–100: how strongly the public evidence ties the cuts to AI. Sources are linked on each one.
AI score 2/100 (Minimal) · 80% interval 2–3 · evidence grade D · US · Pharma / Chemicals
Stated reason: On May 31, 2026, the board of directors of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restructuring plan to significantly reduce Fulcrum’s operating expenses and preserve capital following the discontinuation of development of pociredir for the treatment of sickle cell disease, or SCD. The restructuring plan will reduce Fulcrum’s workforce by approximately 85%, from 57 full-time employees to 9 full-time emplo…
Why 2: Plant, store or site closure · Drivers: contrary evidence −0.9, industry AI exposure +0.5
Evidence: SEC filing. Signals: attribution 0.0, primary source 0.0, exec statement 0.0, role exposure 0.761, industry exposure 0.712, AI investment 0.0, contrary evidence 0.55 · named roles: Computer and Information Systems Managers, General and Operations Managers
Headcount basis: not disclosed
Scores are evidence-based estimates from a published model, not findings that AI caused any layoff. Spot something wrong or missing? Tell us.
Other Health Care & Pharma layoffs we track.
Health Care & Pharma · 1,864 workers
Health Care & Pharma · 589 workers
Health Care & Pharma · 303 workers
Health Care & Pharma · 87 workers
Health Care & Pharma
Health Care & Pharma
